FDA approves first pill to help treat postpartum depression

The Food and Drug Administration (FDA) has approved the first pill to treat postpartum depression (PPD). announced on friday.

Zurzuvae is the first tablet drug on the market for this disease, which can occur in many cases, in mild cases. 50 percent about new mothers.

“Postpartum depression is a serious and potentially life-threatening condition in which women experience feelings of sadness, guilt, worthlessness, and, in severe cases, harm to themselves and their children. It even makes me think,” FDA Psychiatry Director Tiffany Falchione said in a statement.

“For many women dealing with extreme and sometimes life-threatening emotions, the availability of oral medications could be a beneficial option.”

Two randomized studies confirmed that the flies were effective in combating PPD, and one study showed that symptoms improved by about 55 percent in women with PPD, according to the agency.

A pill taken once a day can help relieve symptoms of depression in a matter of days instead of weeks or months like traditional antidepressants usually prescribed for depression.

Manufacturer Sage Therapeutics released a similar drug in 2019, the first ever to combat PPD. However, its product Zurlesso is an intravenous drip, which is inconvenient for most new mothers.

Zurzvae will now enter the Drug Enforcement Administration’s approval process, which is expected to take about 90 days.

Last year, the FDA approved the first fast-acting pill to combat clinical depression. Experts said the drug, which uses a novel therapeutic mechanism, could open the door to a new set of treatments for depression.